Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and InformationThe implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor specimens not previously released. These data include exome and RNA level characterization as well as analyses of ex vivo drug sensitivity. Collectively, this data can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of leukemia in pediatric and AYA populations.
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
- Study Design:
- Case Set
- Study Type:
- Case Set
- Exome Sequencing
- RNA Sequencing
- Total number of consented subjects: 104
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Pediatric and AYA (< 40 years old) leukemia patients at diagnosis.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Leukemia, Myeloid, Acute
- Neoplasms
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Jeffrey Tyner, PhD. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
-
Funding Sources
- Leukemia and Lymphoma Society. Rye Brook, NY, USA.
- 5P30CA069533. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator